KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) Enterprise Value (2016 - 2025)

Sarepta Therapeutics has reported Enterprise Value over the past 16 years, most recently at -$939.6 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 14.26% year-over-year to -$939.6 million; the TTM value through Dec 2025 reached -$939.6 million, up 14.26%, while the annual FY2025 figure was -$939.6 million, 14.26% up from the prior year.
  • Enterprise Value for Q4 2025 was -$939.6 million at Sarepta Therapeutics, down from -$851.0 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$242.5 million in Q3 2024 and troughed at -$2.1 billion in Q4 2021.
  • A 5-year average of -$1.5 billion and a median of -$1.7 billion in 2021 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: surged 86.01% in 2024 and later tumbled 250.97% in 2025.
  • Year by year, Enterprise Value stood at -$2.1 billion in 2021, then increased by 5.98% to -$2.0 billion in 2022, then rose by 15.74% to -$1.7 billion in 2023, then surged by 34.62% to -$1.1 billion in 2024, then increased by 14.26% to -$939.6 million in 2025.
  • Business Quant data shows Enterprise Value for SRPT at -$939.6 million in Q4 2025, -$851.0 million in Q3 2025, and -$800.1 million in Q2 2025.